The European Commission is launching a selection procedure to appoint 6 independent scientific expert specialists in pharmacovigilance as members of the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC).
The PRAC is a key actor for the assessment and monitoring of the safety of medicines. It is composed of one member appointed by each Member State, one representative of patient organisations, one representative of healthcare professional and the 6 scientific experts. The independent experts are expected to prepare and attend the monthly meeting, actively participate in its scientific discussions and provide comments on documents. The experts are meant to complement the expertise provided by other members of the committee.
Expression of interest should be submitted to the European Commission by 30 September 2017. Experts will be appointed for a period of 3 years starting 2 July 2018 which may be extended once and renewed. Current experts may reapply for their position.
Additional information about the assessment criteria and application process can be found on the European Commission website here.